PCSK9 and familial hypercholesterolemia: Our study demonstrates that therapy with the PCSK9 inhibitors evolocumab and alirocumab lead to a significant reduction of LDL Cholesterol in heart transplantation recipients with hypercholesterolemia and therapeutic failure of statin regimens or statin intolerance.